# Escalation of Doses of Daratumumab in Combination With Chemotherapy (Idarubicin and Cytarabine) in Patients of 60 Years Old or More With Adverse Risk Acute Myeloblastic Leukemia (AML) (DARALAM)

> **NCT05749276** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Nantes University Hospital** · enrollment: 12 (estimated)

## Conditions studied

- Adult Patients With Adverse Risk Acute Myeloblastic Leukemia

## Interventions

- **DRUG:** Darzalex

## Key facts

- **NCT ID:** NCT05749276
- **Lead sponsor:** Nantes University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-05
- **Primary completion:** 2028-01
- **Final completion:** 2028-01
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2024-04-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05749276

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05749276, "Escalation of Doses of Daratumumab in Combination With Chemotherapy (Idarubicin and Cytarabine) in Patients of 60 Years Old or More With Adverse Risk Acute Myeloblastic Leukemia (AML) (DARALAM)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05749276. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*